This site is intended for Healthcare Professionals outside the US

JAKAVI demonstrated durable haematocrit control with fewer phlebotomies1-4

JAKAVI maintained durable, continuous haematocrit control1,2

  • Three times as many patients attained the primary endpoint component of haematocrit control* without phlebotomy (60% with JAKAVI vs 20% with BAT)1,2

Haematocrit levels over time1,2

JAK2 Inhibitor treatment (JAKAVI) for Polycythemia Vera demonstrated durable, continuous haematocrit control
  • Mean haematocrit level over time was an exploratory analysis
  • In a Phase II study, long-term haematocrit control was observed among patients receiving JAKAVI5
    • 61% of patients maintained haematocrit <45% without phlebotomy at 144 weeks5

JAKAVI reduced the need for phlebotomy3,4

  • Patients in the BAT arm had higher mean haematocrit levels despite a higher number of phlebotomies2-4

Number of phlebotomies needed between Weeks 8 and 324

JAK2 Inhibitor, JAKAVI, reduced the need for phlebotomy in Polycythemia Vera patients

Includes patients who did not discontinue randomised treatment prior to Week 8.

  • Number of phlebotomies received was an exploratory analysis

Next: JAKAVI helps control multiple haematologic parameters

*Haematocrit control was defined as the absence of phlebotomy eligibility from Week 8 to Week 32, with no more than one post-randomisation phlebotomy allowed prior to Week 8. Phlebotomy eligibility was defined as haematocrit >45% and ≥3% higher than baseline or >48%, whichever was lower.1,2

BAT=best available therapy.

References:

  1. JAKAVI® (ruxolitinib) tablets: EU Summary of Product Characteristics. Novartis; April 2015.
  2. Data on file. Novartis Pharma AG. Basel, Switzerland.
  3. Vannucchi AM, Kiladjian JJ, Griesshammer M, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015;372(5):426-435.
  4. Vannucchi AM, Kiladjian JJ, Griesshammer M, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera [supplementary appendix]. N Engl J Med. 2015;372(5):1-25.
  5. Verstovsek S, Passamonti F, Rambaldi A, et al. A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. Cancer. 2014;120(4):513-520.